Relieves cancer cells in 15 days, 'broad-spectrum anticancer drug' is approved for marketing in China, who can afford 2.5 million?

It is a good thing that more and more anti-cancer scientific and technological achievements can be applied, but the price is desperate! Recently, larottinib, the first broad-spectrum anticancer drug, was approved for marketing in China, but netizens complained. According to foreign data, the cost of using larottinib for one year exceeds 2.5 million, which is called "astronomical price"! So, is such an expensive anticancer drug worth it?

Directly hit the lesion, the guided attack of larottinib

According to data released by the World Health Organization's International Agency for Research on Cancer, there are 19.29 million new cancer cases worldwide, and only 4.57 million new cancer cases in China, of which the number of new cases and deaths ranks first in the world. The emergence of "special drugs" such as larottinib regardless of cancer type will undoubtedly bring more hope to cancer patients.

In fact, larottinib was not independently developed by China, but was jointly developed by two foreign biological companies, and was approved by the US FDA in 2018 and has been used abroad for many years. It can be seen that larottinib is indeed effective in the corresponding cancer treatment.

So, how does larotrectinib work? Larotrectinib (Vitrakvi) is a tumor-targeted drug that specifically targets NTRK gene fusions. It is effective for these patients regardless of the type of cancer.

The NTRK gene is involved in the development, function and cell survival of the nervous system in healthy tissues, but fusion of any gene in its family with other genes to produce an abnormal protein promotes tumor growth and spread. Larotrectinib is a newly discovered small molecule kinase inhibitor, which can accurately attack cancer cells in the body and avoid accidental injury to normal cells, with low toxicity and small side effects.

According to the data released at the 2021 ASCO Oncology Conference, the overall response rate of larotrectinib is as high as 75%, covering 17 different cancer types such as colon, lung, pancreas, and gastrointestinal tract. It is a veritable "broad-spectrum anti-cancer drug". !

"The emergence of larottinib has brought good hope for survival to patients with NTRK gene fusion tumors." Xu Weifeng, a physician at Henan Cancer Hospital, said in an interview before, "Although such patients are difficult to find, as long as larotib is used Nepal can be effectively relieved, and it is a very good 'special medicine'."

The standard treatment course of larotrectinib is one month. Usually, the patients with better adaptability can see the effect in 15 days, and the slower patients may see the effect in one month. Before larottinib was approved for marketing in China, many patients with NTRK gene fusion tumors improved because of it.

The pro-testers have lived a life of "family happiness"

Without considering the cost, larotrectinib is really good for anti-cancer!

A foreign patient named John Peachey was diagnosed with stage IV non-small cell lung cancer in 2013, and the tumor had metastasized to the brain, liver and bone. After more than 6 years of painful chemotherapy and radiation therapy, he started larotrectinib in 2019, and soon showed good results, and a follow-up MRI of the brain, CT scan of the chest and pelvis showed no new cancer, some tumors shrank, Some have disappeared.

Now he has completely returned to his normal life, watching his children get married and his grandsons are born. From father to grandfather, the company of his children and grandchildren makes him very happy and enjoys the "family happiness" on earth.

Similar to him is an 81-year-old man who was diagnosed with advanced pancreatic cancer. After a variety of adjuvant therapies after surgery, he was relieved, and the disease progressed wildly. He also developed liver metastases, and 3 cases of different sizes appeared. The lesions, he thought he would not survive, but after spending over 200,000 per month and taking Lalo for you twice a day, his condition was relieved. One year later, the imaging examination showed that the old man's liver lesions almost disappeared.

There are countless cases of larottinib saving the lives of others, but the cost of such an effective "anti-cancer drug" is really not low!

Who can use the 2.5 million "sky price"?

In the United States, the cost of oral capsule larottinib for a year is about 2.5 million; in Hong Kong, the annual cost is as high as more than 3.4 million. After reading it, netizens called out: Such a "high price", who can use it?

At present, larottinib has been approved for listing in China, but the specific price is yet to be determined. I hope it will be cheaper or the relevant costs can be included in medical insurance. However, the high cost of larotrectinib is understandable. After all, this type of anticancer drug uses few patients and has high research and development costs. Just like the WLife substances developed by the Harvard laboratory, because of its ability to extend human telomeres, delay The body is aging, and when it first came out of the laboratory, the price was as high as 200,000 / gram.

In recent years, Lee, the richest man in Hong Kong, has spent 200 million to help his technology research and development after trying this kind of substance. With the introduction of WLife R&D technology by domestic biotechnology company Lightweijian, its cost has been reduced by more than 90%, and it has been as low as four digits (refer to the domestic Jing-dong platform), which once caused a wave of out-of-stocks. At present, the domestic research on larottinib is also in full swing. It is believed that in the near future, cheaper larottinib will appear, and the threshold for use will be greatly reduced.

Although scientific research has never stopped, and various anti-cancer results have been emerging, for cancer, keeping your mouth shut and opening your legs, regular physical examinations, and paying attention to health and wellness are the best ways to stay away from it. With the application of larotrectinib, yttrium-90 microspheres and BNCT anti-cancer boron drug CAR-T technology, cancers that were previously considered incurable have become no longer scary.

Ending egg: At present, the trial of larotrectinib for adult solid tumors is still undergoing clinical recruitment in China, and a number of NTRK inhibitors independently developed in the United States and China have been officially approved for clinical trials in China. If you have this need, you can ask the relevant oncology institution.